Adolor regains Entereg rights

Adolor Corp. (NASDAQ:ADLR) will regain full U.S. rights from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to Entereg alvimopan to treat postoperative ileus (POI). The partners currently co-promote the product in the U.S. Adolor said on a conference call it expects to achieve better sales productivity for Entereg by using its own sales force, which would be completely focused on Entereg. GSK will receive $25 million over six years and is eligible for a one-time sales milestone of $15 million, plus tiered, single-digit royalties. Entereg recorded 2010 sales $25.4 million. The deal is expected to close in September. Adolor gained $0.07 to $1.59 on Wednesday. ...